Meta AnalysisID 7363
银杏二萜内酯联合丁苯酞治疗急性脑梗死的有效性与安全性Meta分析
CRD42023445014
What is the impact of ginkgo biloba diterpenoid lactone meglumine combined with butylphthalide on acute cerebral infarction compared to monotherapy?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7363
- Evidence Id
- 15921
- Core Evidence Id
- 15921
- Source Meta Analysis Id
- 7349
- Herb2 Meta Analysis Id
- HBMA007349
- Crd Id
- CRD42023445014
- Title
- Meta-analysis of the efficacy and safety of Ginkgo diterpene lactoneoside combined with butylphthalide in the treatment of acute cerebral infarction
- Review Question
- What is the impact of ginkgo biloba diterpenoid lactone meglumine combined with butylphthalide on acute cerebral infarction compared to monotherapy?
- Study Type Included
- All randomized controlled trials, regardless of blinding, were included.
- Condition Being Studied
- Ginkgolide Meglumine Injection (GMI), as a traditional Chinese medicine compound preparation, has been widely used in the treatment of cerebrovascular diseases in China and has shown certain therapeutic effects. Danaparoid sodium, a commonly used neuroprotective drug, is believed to have therapeutic effects against cerebral ischemia. Although some trials and studies have reported that the combination of Ginkgolide Meglumine and Danaparoid sodium has higher clinical efficacy in the treatment of acute ischemic stroke, systematic analysis of these small-sample clinical trials is currently lacking.
- Participant
- Inclusion: Acute myocardial infarction patients receiving the combination treatment of ginkgo biloba diterpenolide glucosamine and butylphthalide. Exclusion: Non myocardial infarction patients
- Animal
- Human Disease Modelled
- Intervention
- The control group received treatment with butylidenephthalide or ginkgolide glucosamine alone, while the experimental group received combined treatment with ginkgolide glucosamine and butylidenephthalide.
- Comparator Control
- Control group: treated with butylphthalide or ginkgolide glucosamine alone Experimental group: treated with a combination of ginkgo biloba diterpenoid lactone glucosamine and butylphthalide.
- Main Outcome
- Outcome measures: The primary outcome measure was effective rate. The evaluation criteria for effectiveness were as follows: significant improvement: NIHSS score reduction of 46% or more after treatment; effective: NIHSS score of 18% to 45% after treatment; ineffective: NIHSS score reduction of less than 18% after treatment. The total effective rate of treatment was calculated as (number of significantly improved cases + number of effective cases) divided by the total number of cases.
- Outcome Measure
- Additional Outcome
- Secondary outcome measures included NIHSS score, ADL score, plasma viscosity, C-reactive protein, TNF-α, and adverse reactions.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- 3-n-butylphthalide; Brain Ischemia; Diterpenes; Ginkgo biloba; Humans; Infarction; Lactones; Meglumine; Stroke
- Contact
- LI XINSHUAI [email protected]
- Organisational Affiliation
- Nantong First People's Hospital
- Funding Source
- Scientific Research Fund for Young Medical Talents of Nantong Health and Family Planning Commission (QB2019002); Nantong Science and Technology Plan (Guidance) Project (JCZ20076).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-07-14
- Registration Date
- 2023-07-24
- Anticipated Start Date
- 2023-07-14
- Anticipated Completion Date
- 2023-08-24
- Title Cn
- 银杏二萜内酯联合丁苯酞治疗急性脑梗死的有效性与安全性Meta分析
- Title En
- Meta-analysis of the efficacy and safety of Ginkgo diterpene lactoneoside combined with butylphthalide in the treatment of acute cerebral infarction
- Bilingual Status
- complete